These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 21223477)

  • 1. The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines.
    Pesch B; Nasterlack M; Eberle F; Bonberg N; Taeger D; Leng G; Feil G; Johnen G; Ickstadt K; Kluckert M; Wellhäusser H; Stenzl A; Brüning T;
    BJU Int; 2011 Aug; 108(4):546-52. PubMed ID: 21223477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study.
    Huber S; Schwentner C; Taeger D; Pesch B; Nasterlack M; Leng G; Mayer T; Gawrych K; Bonberg N; Pelster M; Johnen G; Bontrup H; Wellhäusser H; Bierfreund HG; Wiens C; Bayer C; Eberle F; Scheuermann B; Kluckert M; Feil G; Brüning T; Stenzl A;
    BJU Int; 2012 Sep; 110(5):699-708. PubMed ID: 22313585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosomal instability and bladder cancer: the UroVysion(TM) test in the UroScreen study.
    Bonberg N; Taeger D; Gawrych K; Johnen G; Banek S; Schwentner C; Sievert KD; Wellhäußer H; Kluckert M; Leng G; Nasterlack M; Stenzl A; Behrens T; Brüning T; Pesch B;
    BJU Int; 2013 Aug; 112(4):E372-82. PubMed ID: 23350736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
    Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
    BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early results of bladder-cancer screening in a high-risk population of heavy smokers.
    Steiner H; Bergmeister M; Verdorfer I; Granig T; Mikuz G; Bartsch G; Stoehr B; Brunner A
    BJU Int; 2008 Aug; 102(3):291-6. PubMed ID: 18336612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines.
    Pesch B; Taeger D; Johnen G; Gawrych K; Bonberg N; Schwentner C; Wellhäusser H; Kluckert M; Leng G; Nasterlack M; Lotan Y; Stenzl A; Brüning T;
    Int Arch Occup Environ Health; 2014; 87(7):715-24. PubMed ID: 24129706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bladder cancer screening with urine-based tumour markers - occupational medical experience].
    Nasterlack M; Feil G; Leng G; Pesch B; Huber S; Sievert KD; Johnen G; Taeger D; Mayer T; Kluckert M; Brüning T; Stenzl A
    Aktuelle Urol; 2011 Mar; 42(2):128-34. PubMed ID: 21437837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection.
    Lotan Y; Shariat SF;
    BJU Int; 2008 Jun; 101(11):1362-7. PubMed ID: 18284410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection.
    Lotan Y; Capitanio U; Shariat SF; Hutterer GC; Karakiewicz PI
    BJU Int; 2009 May; 103(10):1368-74. PubMed ID: 19338566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer.
    Kehinde EO; Al-Mulla F; Kapila K; Anim JT
    Scand J Urol Nephrol; 2011 Mar; 45(2):113-21. PubMed ID: 21091091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation of fluorescence-in situ-hybridization to detect bladder cancer: results from the UroScreen-Study.
    Banek S; Schwentner C; Täger D; Pesch B; Nasterlack M; Leng G; Gawrych K; Bonberg N; Johnen G; Kluckert M; Gakis G; Todenhöfer T; Hennenlotter J; Brüning T; Stenzl A;
    Urol Oncol; 2013 Nov; 31(8):1656-62. PubMed ID: 22621963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for bladder tumours in men aged 60-70 years with a bladder tumour marker (UBC) and dipstick-detected haematuria using both white-light and fluorescence cystoscopy.
    Hedelin H; Jonsson K; Salomonsson K; Boman H
    Scand J Urol Nephrol; 2006; 40(1):26-30. PubMed ID: 16452052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening and monitoring for bladder cancer: refining the use of NMP22.
    Ponsky LE; Sharma S; Pandrangi L; Kedia S; Nelson D; Agarwal A; Zippe CD
    J Urol; 2001 Jul; 166(1):75-8. PubMed ID: 11435827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.
    Moonen PM; Kiemeney LA; Witjes JA
    Eur Urol; 2005 Dec; 48(6):951-6; discussion 956. PubMed ID: 16257108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective external validation of a bladder cancer detection model.
    Lotan Y; Svatek RS; Krabbe LM; Xylinas E; Klatte T; Shariat SF
    J Urol; 2014 Nov; 192(5):1343-8. PubMed ID: 24859442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
    Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
    Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes in a high-risk bladder cancer screening cohort.
    Starke N; Singla N; Haddad A; Lotan Y
    BJU Int; 2016 Apr; 117(4):611-7. PubMed ID: 25891519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers.
    Bangma CH; Loeb S; Busstra M; Zhu X; El Bouazzaoui S; Refos J; Van Der Keur KA; Tjin S; Franken CG; van Leenders GJ; Zwarthoff EC; Roobol MJ
    Eur Urol; 2013 Jul; 64(1):41-7. PubMed ID: 23478169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.
    Zippe C; Pandrangi L; Agarwal A
    J Urol; 1999 Jan; 161(1):62-5. PubMed ID: 10037369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project).
    Roobol MJ; Bangma CH; el Bouazzaoui S; Franken-Raab CG; Zwarthoff EC
    Urol Oncol; 2010; 28(6):686-90. PubMed ID: 21062653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.